Product Code Database
Example Keywords: handheld -grand $87
   » » Wiki: Scleroderma
Tag Wiki 'Scleroderma'.
Tag

Scleroderma is a group of autoimmune diseases that may result in changes to the , , , and . The disease can be either localized to the skin or involve other organs as well. Symptoms may include areas of thickened skin, stiffness, feeling tired, and poor blood flow to the fingers or toes with cold exposure. One form of the condition, known as , classically results in , Raynaud's syndrome, problems, , and .

The cause is unknown, but it may be due to an abnormal immune response. Risk factors include family history, certain factors, and exposure to . The underlying mechanism involves the abnormal growth of connective tissue, which is believed to be the result of the immune system attacking healthy tissues. Diagnosis is based on symptoms, supported by a or blood tests.

While no cure is known, treatment may improve symptoms. Medications used include , , and non-steroidal anti-inflammatory drugs (NSAIDs). Outcome depends on the extent of disease. Those with localized disease generally have a normal .

(2026). 9781594548710, Nova Publishers. .
In those with systemic disease, life expectancy can be affected, and this varies based on subtype. Death is often due to lung, gastrointestinal, or heart complications.

About three per 100,000 people per year develop the systemic form. The condition most often begins in middle age. Women are more often affected than men. Scleroderma symptoms were first described in 1753 by Carlo Curzio

(2026). 9780080454740, Academic Press. .
and then well documented in 1842.
(2026). 9781437717389, Elsevier Health Sciences. .
The term is from the skleros meaning "hard" and derma meaning "skin"., .


Signs and symptoms
Potential signs and symptoms include:
(2026). 9780071748896, McGraw-Hill Professional.
  • Cardiovascular: Raynaud's phenomenon (is the presenting symptom in 30% of affected persons, occurs in 95% of affected individuals at some time during their illness); healed pitting on the fingertips; skin and mucosal ; , irregular heart rate and fainting due to conduction abnormalities, , and congestive heart failure
  • Digestive: gastroesophageal reflux disease, bloating, , loss of appetite, alternating with , and its complications, gastric antral vascular ectasia, loosening of teeth, and hoarseness (due to acid reflux).
  • Pulmonary: progressive worsening of shortness of breath, chest pain (due to pulmonary artery hypertension), and dry, persistent cough due to interstitial lung disease
  • Musculoskeletal: , , loss of joint range of motion, carpal tunnel syndrome, and
  • Genitourinary: erectile dysfunction, , kidney problems, or
  • Other: facial pain due to trigeminal neuralgia, hand , headache, , fatigue, , and weight loss


Cause
Scleroderma is caused by genetic and environmental factors. Mutations in HLA genes seem to play a crucial role in the of some cases. Many experts believe that early endothelial cell injury and micro-vascular damage act as a key trigger in the disease cascade, linking genetic susceptibility and environmental exposure to immune activation and fibrosis. Likewise , aromatic and chlorinated solvents, , trichloroethylene, fumes, and exposure seems to contribute to the condition in a small proportion of affected persons.


Pathophysiology
Scleroderma is characterised by increased of (leading to the sclerosis), damage to small blood vessels, activation of , and production of altered connective tissue. Its proposed pathogenesis is the following:
  • It begins with an inciting event at the level of the , probably the . The inciting event is yet to be elucidated, but may be a viral agent, , or autoimmune. damage and ensue, leading to the vascular leakiness that manifests in early clinical stages as tissue . At this stage, it is predominantly a Th1- and Th17-mediated disease.
  • After this, the vasculature is further compromised by impaired and impaired (fewer endothelial progenitor cells), likely related to the presence of antiendothelial cell antibodies (AECA). Despite this impaired , elevated levels of pro-angiogenic growth factors such as PDGF and VEGF are often seen in persons with the condition. The balance of and vasoconstriction becomes askew, and the net result is vasoconstriction. The damaged endothelium then serves as a point of origin for blood-clot formation and further contributes to -reperfusion injury and the generation of reactive oxygen species. These later stages are characterised by Th2 polarity.
  • The damaged endothelium upregulates adhesion molecules and to attract , which enables the development of innate and adaptive immune responses, including loss of tolerance to various oxidised , which includes . mature into , which furthers the autoimmune component of the condition. T cells differentiate into subsets, including Th2 cells, which play a vital role in tissue . Anti–topoisomerase 1 , in turn, stimulate type I interferon production.
  • are recruited and activated by multiple and growth factors to generate . Dysregulated transforming growth factor β (TGF-β) signalling in fibroblasts and myofibroblasts has been observed in multiple studies of scleroderma-affected individuals. Activation of fibroblasts and myofibroblasts leads to excessive deposition of collagen and other related proteins, leading to fibrosis. B cells are implicated in this stage, IL-6 and TGF-β produced by the B cells decrease collagen degradation and increase extracellular matrix production. is implicated in the pathophysiology of fibrosis.

is implicated in the pathophysiology of the disease. An inverse correlation between plasma levels of vitamin D and scleroderma severity has been noted, and vitamin D is known to play a crucial role in regulating (usually suppressing) the actions of the immune system.


Diagnosis
Typical scleroderma is classically defined as symmetrical skin thickening, with about 70% of cases also presenting with Raynaud's phenomenon, nail-fold capillary changes, and antinuclear antibodies. Affected individuals may experience systemic organ involvement. No single test for scleroderma works all of the time; hence, diagnosis is often a matter of exclusion. Atypical scleroderma may show any variation of these changes without skin changes or with finger swelling only.

Laboratory testing can show antitopoisomerase antibodies, like anti-scl70 (causing a diffuse systemic form), or anticentromere antibodies (causing a limited systemic form and the CREST syndrome). Other autoantibodies can be seen, such as anti-U3 or anti-RNA polymerase. Antidouble-stranded DNA autoantibodies are likely to be present in serum.


Differential
Diseases that are often in the differential include:
  • is a condition in which too many (a type of immune cell that attacks parasites and is involved in certain allergic reactions) are present in the blood.
  • Eosinophilia-myalgia syndrome is a form of eosinophilia caused by supplements.
  • Eosinophilic fasciitis affects the connective tissue surrounding skeletal muscles, bones, blood vessels, and nerves in the arms and legs.
  • Graft-versus-host disease is an autoimmune condition that occurs as a result of bone-marrow transplants in which the immune cells from the transplanted bone marrow attack the host's body.
  • Mycosis fungoides is a type of cutaneous T cell lymphoma, a rare cancer that causes rashes all over the body.
  • Nephrogenic systemic fibrosis is a condition usually caused by that results in fibrosis (thickening) of the tissues.
  • Primary biliary cirrhosis is an autoimmune disease of the liver.
  • Primary pulmonary hypertension
  • Complex regional pain syndrome


Classification
Scleroderma is characterised by the appearance of circumscribed or diffuse, hard, smooth, ivory-colored areas that are immobile and which give the appearance of hidebound skin, a disease occurring in both localised and systemic forms:
(2026). 9780808923510, Saunders Elsevier. .

  • Localised scleroderma
    • Localised morphea
    • Morphea-lichen sclerosus et atrophicus overlap
    • Generalised morphea
    • Atrophoderma of Pasini and Pierini
    • Pansclerotic morphea
    • Linear scleroderma
  • Systemic scleroderma


Treatment
No cure for scleroderma is known, although relief of symptoms is often achieved; these include treatment of:
  • Raynaud's phenomenon with vasodilators such as calcium channel blockers, , serotonin receptor antagonists, angiotensin II receptor inhibitors, , local nitrates or
  • Digital ulcers with phosphodiesterase 5 inhibitors (e.g., ) or
  • Prevention of new digital ulcers with
  • Malnutrition, secondary to intestinal flora overgrowth with tetracycline antibiotics such as
  • Interstitial lung disease with , with or without corticosteroids
  • Pulmonary arterial hypertension with endothelin receptor antagonists, phosphodiesterase 5 inhibitors, and prostanoids
  • Gastrooesophageal reflux disease with antacids or prokinetics
  • Kidney crises with angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists

Systemic disease-modifying treatment with immunosuppressants is often used. Immunosuppressants used in its treatment include , , , , intravenous , , , , and the tyrosine kinase inhibitors, , , and .

Experimental therapies under investigation include endothelin receptor antagonists, tyrosine kinase inhibitors, beta-glycan peptides, , , , , and haematopoietic stem cell transplantation.

Malignancies, injection site reactions, blood clots, , hepatotoxicity and infections.
and rarely malignancy, hepatitis, infection, hepatic sinusoidal obstruction syndrome and hypersensitivity reactions.
Vomiting, myelosuppression, haemorrhagic cystitis and rarely heart failure, pulmonary fibrosis, hepatic sinusoidal obstruction syndrome, malignancy and SIADH
Fluid retention, myelosuppression, haemorrhage, infections, pulmonary hypertension, electrolyte anomalies and uncommonly hepatotoxicity, heart dysfunction/failure, myocardial infarction, QT interval prolongation, renal failure and hypersensitivity.
As above and rarely: GI perforation, avascular necrosis and
Varies
Myelosuppression, pulmonary toxicity, hepatotoxicity, neurotoxicity, and rarely kidney failure, hypersensitivity reactions, skin and bone necrosis, and osteoporosis
Myelosuppression, blood clots, less commonly GI perforation/haemorrhage and rarely , , and pure red cell aplasia.
As per imatinib
Infusion-related reactions, infection, , reduced immunoglobulin levels, arrhythmias, less commonly anaemia, thrombocytopenia, angina, myocardial infarction, heart failure, and rarely haemolytic anaemia, , serum sickness, severe skin conditions, pulmonary infiltrates, , cranial neuropathy (vision or hearing loss) and progressive multifocal leucoencephalopathy.
, , interstitial lung disease, pericardial effusion, , less commonly pulmonary haemorrhage, nephrotic syndrome, and rarely hepatotoxicity and .
PO = Oral. IV = Intravenous. IM = Intramuscular. SC = Subcutaneous. IT = Intrathecal.
The preferred pregnancy category, above, is Australian, if available. If unavailable, an American one is substituted.


Prognosis
, the five-year survival rate for systemic scleroderma was about 85%, whereas the 10-year survival rate was just under 70%. This varies according to the subtype; while localized scleroderma rarely results in death, the systemic form can, and the diffuse systemic form carries a worse prognosis than the limited form. The major scleroderma-related causes of death are: pulmonary hypertension, pulmonary fibrosis, and scleroderma renal crisis. People with scleroderma are also at a heightened risk for developing osteoporosis and for contracting cancer (especially liver, lung, haematologic, and bladder cancers). Scleroderma is also associated with an increased risk of cardiovascular disease.

According to a study of an Australian cohort, between 1985 and 2015, the average life expectancy of a person with scleroderma increased from 66 years to 74 years (the average Australian life expectancy increased from 76 to 82 years in the same period).


Epidemiology
Scleroderma most commonly first presents between the ages of 20 and 50 years, although any age group can be affected. Women are four to nine times more likely to develop scleroderma than men.

This disease is found worldwide. In the United States, prevalence is estimated at 240 per million, and the annual incidence of scleroderma is 19 per million people. Likewise, in the United States, it is slightly more common in than in their white counterparts. Choctaw Native Americans are more likely than Americans of European descent to develop the type of scleroderma that affects internal organs. In , the prevalence is between 10 and 150 per million people, and the annual incidence is between three and 28 per million people. In , the annual incidence is 23 per million people, and the prevalence 233 per million people.


Pregnancy
Scleroderma in pregnancy is a complex situation; it increases the risk to both mother and child. Overall, scleroderma is associated with reduced fetal weight for gestational age. The treatment for scleroderma often includes known teratogens such as cyclophosphamide, methotrexate, , etc., so careful avoidance of such drugs during pregnancy is advised. In these cases hydroxychloroquine and low-dose might be used for disease control.


See also
  • Congenital fascial dystrophy
  • Chi Chi DeVayne, (developed scleroderma in the years leading up to her death)


External links

Page 1 of 1
1
Page 1 of 1
1

Account

Social:
Pages:  ..   .. 
Items:  .. 

Navigation

General: Atom Feed Atom Feed  .. 
Help:  ..   .. 
Category:  ..   .. 
Media:  ..   .. 
Posts:  ..   ..   .. 

Statistics

Page:  .. 
Summary:  .. 
1 Tags
10/10 Page Rank
5 Page Refs
1s Time